losartan has been researched along with Diabetes Mellitus, Type 1 in 53 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effect of low-dose losartan, an angiotensin II antagonist, on persistent microalbuminuria in normotensive Type 1 diabetes mellitus, 16 subjects with Type 1 diabetes were randomly assigned to two 2-month treatment periods, with either losartan (25 mg/day) or enalapril (5 mg/day) in a single-blind cross-over design." | 9.09 | Effects of low-dose losartan treatment on persistent microalbuminuria in normotensive type 1 diabetic subjects. ( Açbay, O, 2001) |
| "We investigated the effects of dual renin-angiotensin system (RAS) blockade on angiotensin-converting enzyme-2 (Ace2) expression, hypertension, and renal proximal tubular cell (RPTC) apoptosis in type 1 diabetic Akita angiotensinogen (Agt)-transgenic (Tg) mice that specifically overexpress Agt in their RPTCs." | 7.78 | Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. ( Chan, JS; Chenier, I; Filep, JG; Godin, N; Ingelfinger, JR; Liu, F; Lo, CS; Maachi, H; Shi, Y; Zhang, SL, 2012) |
| "Angioedema and cough are known side effects of angiotensin-converting enzyme (ACE) inhibitors." | 5.31 | Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. ( Abdi, R; Dong, VM; Lee, CJ; Ntoso, KA, 2002) |
| "We conducted a multicenter, controlled trial involving 285 normotensive patients with type 1 diabetes and normoalbuminuria and who were randomly assigned to receive losartan (100 mg daily), enalapril (20 mg daily), or placebo and followed for 5 years." | 5.14 | Renal and retinal effects of enalapril and losartan in type 1 diabetes. ( Donnelly, S; Drummond, K; Gardiner, R; Goodyer, P; Gubler, MC; Klein, R; Mauer, M; Sinaiko, A; Strand, T; Suissa, S; Zinman, B, 2009) |
| " We investigated whether this polymorphism is predictive of reductions in blood pressure and albuminuria and preservation of glomerular filtration rate (GFR) during short-term and long-term treatment with losartan in 57 hypertensive type-1 diabetic patients with diabetic nephropathy." | 5.12 | Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. ( Andersen, S; Lajer, M; Parving, HH; Rossing, P; Schjoedt, KJ; Tarnow, L, 2006) |
| "To examine the effect of low-dose losartan, an angiotensin II antagonist, on persistent microalbuminuria in normotensive Type 1 diabetes mellitus, 16 subjects with Type 1 diabetes were randomly assigned to two 2-month treatment periods, with either losartan (25 mg/day) or enalapril (5 mg/day) in a single-blind cross-over design." | 5.09 | Effects of low-dose losartan treatment on persistent microalbuminuria in normotensive type 1 diabetic subjects. ( Açbay, O, 2001) |
| "We investigated the effects of dual renin-angiotensin system (RAS) blockade on angiotensin-converting enzyme-2 (Ace2) expression, hypertension, and renal proximal tubular cell (RPTC) apoptosis in type 1 diabetic Akita angiotensinogen (Agt)-transgenic (Tg) mice that specifically overexpress Agt in their RPTCs." | 3.78 | Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. ( Chan, JS; Chenier, I; Filep, JG; Godin, N; Ingelfinger, JR; Liu, F; Lo, CS; Maachi, H; Shi, Y; Zhang, SL, 2012) |
| "After 12 weeks of the treatment with losartan, albuminuria was reduced from baseline by 9% [95% confidence interval (CI): 1-17, p = 0." | 3.76 | Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate. ( Ajdinović, B; Andelković, Z; Dragović, T; Hrvacević, R; Ilić, V; Kocev, N; Magić, Z, 2010) |
| " Losartan improved both the diabetes-related abnormalities and the diabetic hypertension." | 3.74 | Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK. ( Kamata, K; Kobayashi, T; Matsumoto, T; Nogami, T; Taguchi, K, 2008) |
| "Treatment with losartan potassium or enalapril maleate was not associated with a statistically significant change in CRAE or CRVE." | 2.75 | Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitus. ( Donnelly, SM; Gardiner, R; Goodyer, P; Klein, BE; Klein, R; Mauer, M; Myers, CE; Sinaiko, AR; Strand, T; Suissa, S; Zinman, B, 2010) |
| "Diabetic retinopathy was determined by masked grading of 30 degrees color stereoscopic fundus photographs of 7 standard fields using the Early Treatment Diabetic Retinopathy Study severity scale." | 2.72 | The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin-angiotensin system study. ( Donnelly, SM; Gardiner, R; Goodyer, P; Klein, R; Kramer, MS; Mauer, M; Moss, SE; Sinaiko, AR; Strand, T; Suissa, S; Zinman, B, 2006) |
| "Nine IDDM patients with microalbuminuria (30-300 mg/24 h) were studied." | 2.70 | Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. ( Buter, H; de Jong, PE; de Zeeuw, D; Dullaart, RP; Navis, G, 2001) |
| "The earliest marker of incipient diabetic nephropathy is the transition of normoalbuminuria to microalbuminuria at an albumin excretion rate of 20 microg/min." | 2.42 | Losartan in diabetic nephropathy. ( Perico, N; Remuzzi, G; Ruggenenti, P, 2004) |
| "Type 1 diabetes was induced by a single 60 mg/kg intraperitoneal injection of streptozotocin in Sprague-Dawley rats." | 1.48 | A pan-NADPH Oxidase Inhibitor Ameliorates Kidney Injury in Type 1 Diabetic Rats. ( Bae, YS; Cha, DR; Dorotea, D; Ha, H; Kwon, G; Lee, JH; Lee, SJ; Moon, SH; Saunders, E, 2018) |
| "The AKT-mTOR pathway is activated in diabetic nephropathy." | 1.39 | Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy. ( Daphnis, E; Ganotakis, E; Giannakakis, K; Katsarou, T; Mavroeidi, V; Papavasiliou, S; Perakis, K; Petrakis, I; Stratigis, S; Stylianou, K; Vardaki, E, 2013) |
| "Losartan treatment (100 mg/day) reduced urinary KIM-1 by 43% over a 12-month period." | 1.37 | Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. ( Andersen, S; Hess, G; Nielsen, SE; Parving, HH; Rossing, P; Zdunek, D, 2011) |
| "Angioedema and cough are known side effects of angiotensin-converting enzyme (ACE) inhibitors." | 1.31 | Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. ( Abdi, R; Dong, VM; Lee, CJ; Ntoso, KA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.66) | 18.2507 |
| 2000's | 31 (58.49) | 29.6817 |
| 2010's | 18 (33.96) | 24.3611 |
| 2020's | 1 (1.89) | 2.80 |
| Authors | Studies |
|---|---|
| Buhur, A | 1 |
| Gürel, Ç | 1 |
| Kuşçu, GC | 1 |
| Yiğittürk, G | 1 |
| Oltulu, F | 1 |
| Karabay Yavaşoğlu, NÜ | 1 |
| Uysal, A | 1 |
| Yavaşoğlu, A | 1 |
| Chmiel-Perzyńska, I | 1 |
| Perzyński, A | 1 |
| Olajossy, B | 1 |
| Gil-Kulik, P | 1 |
| Kocki, J | 1 |
| Urbańska, EM | 1 |
| Dorotea, D | 1 |
| Kwon, G | 1 |
| Lee, JH | 1 |
| Saunders, E | 1 |
| Bae, YS | 1 |
| Moon, SH | 1 |
| Lee, SJ | 1 |
| Cha, DR | 1 |
| Ha, H | 1 |
| Mavroeidi, V | 1 |
| Petrakis, I | 1 |
| Stylianou, K | 1 |
| Katsarou, T | 1 |
| Giannakakis, K | 1 |
| Perakis, K | 1 |
| Vardaki, E | 1 |
| Stratigis, S | 1 |
| Ganotakis, E | 1 |
| Papavasiliou, S | 1 |
| Daphnis, E | 1 |
| Montanari, A | 1 |
| Pelà, G | 1 |
| Musiari, L | 1 |
| Crocamo, A | 1 |
| Boeti, L | 1 |
| Cabassi, A | 1 |
| Biggi, A | 1 |
| Cherney, DZ | 2 |
| Zinman, B | 6 |
| Kennedy, CR | 1 |
| Moineddin, R | 1 |
| Lai, V | 1 |
| Yang, S | 1 |
| Miller, JA | 2 |
| Prokopec, SD | 1 |
| Boutros, PC | 1 |
| Scholey, JW | 1 |
| Reich, HN | 1 |
| Robiner, WN | 1 |
| Strand, TD | 2 |
| Mauer, M | 6 |
| Komers, R | 2 |
| Xu, B | 1 |
| Fu, Y | 1 |
| McClelland, A | 1 |
| Kantharidis, P | 1 |
| Mittal, A | 1 |
| Cohen, HT | 1 |
| Cohen, DM | 1 |
| Ezel, T | 1 |
| Kocyigit, Y | 1 |
| Deveci, E | 1 |
| Atamer, Y | 1 |
| Sermet, A | 1 |
| Uysal, E | 1 |
| Aktaş, A | 1 |
| Yavuz, D | 1 |
| Kobayashi, T | 1 |
| Nogami, T | 1 |
| Taguchi, K | 1 |
| Matsumoto, T | 1 |
| Kamata, K | 1 |
| Gardiner, R | 4 |
| Suissa, S | 4 |
| Sinaiko, A | 2 |
| Strand, T | 3 |
| Drummond, K | 1 |
| Donnelly, S | 1 |
| Goodyer, P | 3 |
| Gubler, MC | 1 |
| Klein, R | 5 |
| Myers, CE | 1 |
| Klein, BE | 1 |
| Sinaiko, AR | 3 |
| Donnelly, SM | 3 |
| Naviglio, S | 1 |
| Pirozzi, F | 1 |
| Dragović, T | 1 |
| Ajdinović, B | 1 |
| Hrvacević, R | 1 |
| Ilić, V | 1 |
| Magić, Z | 1 |
| Andelković, Z | 1 |
| Kocev, N | 1 |
| Sjølie, AK | 1 |
| Dodson, P | 1 |
| Hobbs, FR | 1 |
| Nielsen, SE | 1 |
| Andersen, S | 9 |
| Zdunek, D | 1 |
| Hess, G | 1 |
| Parving, HH | 9 |
| Rossing, P | 7 |
| Harindhanavudhi, T | 1 |
| Caramori, ML | 1 |
| Demová, H | 1 |
| Cerná, M | 1 |
| Lo, CS | 1 |
| Liu, F | 1 |
| Shi, Y | 1 |
| Maachi, H | 1 |
| Chenier, I | 1 |
| Godin, N | 1 |
| Filep, JG | 1 |
| Ingelfinger, JR | 1 |
| Zhang, SL | 1 |
| Chan, JS | 1 |
| Yousif, MH | 1 |
| Dhaunsi, GS | 1 |
| Makki, BM | 1 |
| Qabazard, BA | 1 |
| Akhtar, S | 1 |
| Benter, IF | 1 |
| Zhang, L | 1 |
| Xiong, XQ | 1 |
| Fan, ZD | 1 |
| Gan, XB | 1 |
| Gao, XY | 1 |
| Zhu, GQ | 1 |
| Abdi, R | 1 |
| Dong, VM | 1 |
| Lee, CJ | 1 |
| Ntoso, KA | 1 |
| Jacobsen, P | 1 |
| Tarnow, L | 7 |
| Juhl, TR | 2 |
| Drummond, KN | 1 |
| Kramer, MS | 2 |
| Cambien, F | 1 |
| Deinum, J | 1 |
| Bramlage, P | 1 |
| Wittchen, HU | 1 |
| Pittrow, D | 1 |
| Dikow, R | 1 |
| Kirch, W | 1 |
| Lehnert, H | 1 |
| Ritz, E | 1 |
| Nielsen, S | 2 |
| Lihn, AS | 1 |
| ØStergaard, T | 1 |
| Mogensen, CE | 2 |
| Schmitz, O | 2 |
| Simkova, R | 1 |
| Kazdova, L | 1 |
| Ruzickova, J | 1 |
| Pelikanova, T | 1 |
| Perico, N | 1 |
| Ruggenenti, P | 1 |
| Remuzzi, G | 1 |
| Schjoedt, KJ | 2 |
| van Nieuwenhoven, FA | 1 |
| Rossing, K | 1 |
| Wieten, L | 1 |
| Goldschmeding, R | 1 |
| Kim, MJ | 1 |
| Lee, DH | 1 |
| Park, DB | 1 |
| Kang, HW | 1 |
| An, CS | 1 |
| Cui, XJ | 1 |
| Kang, JS | 1 |
| Kim, JL | 1 |
| Lee, YJ | 1 |
| Jung, KW | 1 |
| Baumgart, P | 1 |
| Lajer, M | 2 |
| Moss, SE | 1 |
| Chipitsyna, G | 1 |
| Gong, Q | 1 |
| Gray, CF | 1 |
| Haroon, Y | 1 |
| Kamer, E | 1 |
| Arafat, HA | 1 |
| Nuwayri-Salti, N | 1 |
| Karam, CN | 1 |
| Al Jaroudi, WA | 1 |
| Usta, JA | 1 |
| Maharsy, WM | 1 |
| Bitar, KM | 1 |
| Bikhazi, AB | 1 |
| de Cavanagh, EM | 1 |
| Ferder, L | 1 |
| Toblli, JE | 1 |
| Piotrkowski, B | 1 |
| Stella, I | 1 |
| Fraga, CG | 1 |
| Inserra, F | 1 |
| Arrick, DM | 1 |
| Sharpe, GM | 1 |
| Sun, H | 1 |
| Mayhan, WG | 1 |
| Cohen, LS | 1 |
| Friedman, EA | 1 |
| Ottlecz, A | 1 |
| Bensaoula, T | 1 |
| Eichberg, J | 1 |
| Peterson, RG | 1 |
| Hansen, BV | 1 |
| Schalkwijk, CG | 1 |
| Stehouwer, CD | 1 |
| Buter, H | 2 |
| van Tol, A | 1 |
| Navis, GJ | 1 |
| Scheek, LM | 1 |
| de Jong, PE | 2 |
| de Zeeuw, D | 2 |
| Dullaart, RP | 2 |
| Collis, J | 1 |
| Cheetham, C | 1 |
| Dembo, L | 1 |
| O'Driscoll, J | 1 |
| Stanton, K | 1 |
| Taylor, R | 1 |
| Green, D | 1 |
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Abe, A | 1 |
| Imasawa, T | 1 |
| Hosoya, T | 1 |
| Matsumura, M | 1 |
| Navis, G | 1 |
| Açbay, O | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Hove, KY | 1 |
| Dollerup, J | 1 |
| Poulsen, PL | 1 |
| Christiansen, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Renin Angiotensin System Blockage-DN (RASS)[NCT00143949] | Phase 2 | 285 participants (Actual) | Interventional | 1997-03-31 | Completed | ||
| Losartan and ET-1 Mediated Constriction in Postmenopausal Women With High Blood Pressure[NCT03371823] | Phase 4 | 8 participants (Actual) | Interventional | 2017-09-01 | Terminated (stopped due to We experienced challenges recruiting unmedicated women with high blood pressure for the intervention.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cutaneous blood flow is measured via laser Doppler flowmetry during cutaneous microdialysis perfusions of ET-A and ET-B receptor antagonists as previously described by Wenner MM in 2017(see reference list). (NCT03371823)
Timeframe: Each participant was assessed at baseline and 2 weeks later.
| Intervention | % change blood flow flux (Mean) | |
|---|---|---|
| ETA blockade | ETB blockade | |
| Normotensive | 437 | 42 |
3 reviews available for losartan and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2011 |
Losartan in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabe | 2004 |
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; D | 2001 |
20 trials available for losartan and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Nitric oxide-angiotensin II interactions and renal hemodynamic function in patients with uncomplicated type 1 diabetes.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Case-Control Studies; Di | 2013 |
Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chemokines | 2013 |
Adherence and renal biopsy feasibility in the Renin Angiotensin-System Study (RASS) primary prevention diabetes trial.
Topics: Adolescent; Adult; Antihypertensive Agents; Biopsy; Diabetes Mellitus, Type 1; Diabetic Nephropathie | 2013 |
Renal and retinal effects of enalapril and losartan in type 1 diabetes.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2009 |
Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitus.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2010 |
Benefits of Renin-Angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic | 2011 |
ACE-I and ARBs in early diabetic nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Diabetes | 2002 |
Increased plasma adiponectin in losartan-treated type 1 diabetic patients. a mediator of improved insulin sensitivity?
Topics: Adiponectin; Adult; Angiotensin Receptor Antagonists; Blood Glucose; Cross-Over Studies; Diabetes Me | 2004 |
Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; | 2004 |
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.
Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Melli | 2004 |
Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cytochrome P-450 CYP11B | 2006 |
The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin-angiotensin system study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pres | 2006 |
Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Blood Pressure; Cross-Over Studies; Diabete | 1999 |
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2000 |
Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2000 |
Angiotensin II receptor antagonist treatment lowers plasma total and very low + low density lipoprotein cholesterol in Type 1 diabetic patients with albuminuria without affecting plasma cholesterol esterification and cholesteryl ester transfer.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Cholesterol; Cholesterol, LDL; Cholesterol, VL | 2000 |
Losartan, an angiotensin type 1 receptor inhibitor, and endothelial vasodilator function in Type 1 diabetes mellitus.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cross-Over Studies; Diabet | 2000 |
Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, T | 2001 |
Effects of low-dose losartan treatment on persistent microalbuminuria in normotensive type 1 diabetic subjects.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, | 2001 |
Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory | 2001 |
30 other studies available for losartan and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Is losartan a promising agent for the treatment of type 1 diabetes-induced testicular germ cell apoptosis in rats?
Topics: Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Germ Cells; Losartan | 2023 |
Losartan Reverses Hippocampal Increase of Kynurenic Acid in Type 1 Diabetic Rats: A Novel Procognitive Aspect of Sartan Action.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2019 |
A pan-NADPH Oxidase Inhibitor Ameliorates Kidney Injury in Type 1 Diabetic Rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dose-Re | 2018 |
Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Disease Models, Animal; Kidney Glomerulu | 2013 |
Transcriptome-based analysis of kidney gene expression changes associated with diabetes in OVE26 mice, in the presence and absence of losartan treatment.
Topics: Amino Acid Transport System y+; Angiotensin Receptor Antagonists; Animals; Diabetes Mellitus, Type 1 | 2014 |
Biochemical and Histopathological Investigation of Resveratrol, Gliclazide, and Losartan Protective Effects on Renal Damage in a Diabetic Rat Model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Diabetes Mellitus, Experimental; Dia | 2015 |
Diabetic state, high plasma insulin and angiotensin II combine to augment endothelin-1-induced vasoconstriction via ETA receptors and ERK.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Diabetes Mellitus, Experime | 2008 |
Renin-Angiotensin system blockade for diabetic nephropathy prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Typ | 2010 |
Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure | 2010 |
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy.
Topics: Acute-Phase Proteins; Adult; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Fatty Ac | 2011 |
RhoA distribution in renal caveolar fractions in experimental type 1 diabetes.
Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Western; Caveolae; Caveolin 1; Diabetes Mellitu | 2011 |
Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enz | 2012 |
Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Captopril; Cardiovascular S | 2012 |
Involvement of enhanced cardiac sympathetic afferent reflex in sympathetic activation in early stage of diabetes.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Bradykinin | 2012 |
Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema.
Topics: Adult; Angioedema; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2002 |
Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Type 1; | 2003 |
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Cholesterol, HDL; Creatinine; Diabetes | 2003 |
[Microalbuminuria is an early marker for increased morbidity and mortality].
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biom | 2003 |
Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy.
Topics: Adult; Connective Tissue Growth Factor; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; G | 2005 |
Chronic blockade of the angiotensin II receptor has a differential effect on adipose and vascular PAI-1 in OLETF rats.
Topics: Adipose Tissue; Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Aorta, Thoracic; Diabete | 2006 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Induction of monocyte chemoattractant protein-1 expression by angiotensin II in the pancreatic islets and beta-cells.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Line, Tumor; Chemokine CCL2; | 2007 |
CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy.
Topics: Aged; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diabetes Mell | 2007 |
Effect of type-1 diabetes mellitus on the regulation of insulin and endothelin-1 receptors in rat hearts.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Type 1; Endothelin-1; Fluorescent Antibody Technique; | 2007 |
Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; | 2008 |
Losartan improves impaired nitric oxide synthase-dependent dilatation of cerebral arterioles in type 1 diabetic rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arterioles; Cerebral Arteries; Cerebrovascular Dis | 2008 |
Losartan-induced azotemia in a diabetic recipient of a kidney transplant.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1996 |
Angiotensin-converting enzyme activity in retinas of streptozotocin-induced and Zucker diabetic rats. The effect of angiotensin II on Na+,K(+)-ATPase activity.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Experimenta | 1996 |
Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; C | 2000 |
Mannitol-induced toxicity in a diabetic patient receiving losartan.
Topics: Acute Kidney Injury; Antihypertensive Agents; Diabetes Mellitus, Type 1; Diuretics, Osmotic; Drug Hy | 2001 |